• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Live Link
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • News
    • Careers

Get started
Sign in
Close
Inside The Race To Harness Real-World Data: Who Will Build Healthcare’s Most Powerful Platform?

Inside The Race To Harness Real-World Data: Who Will Build Healthcare’s Most Powerful Platform?

by Ryan Klingler | Sep 5, 2025 | Media

A pharmacy benefit manager stopped covering a GLP-1 for obesity. Now there’s a lawsuit

A pharmacy benefit manager stopped covering a GLP-1 for obesity. Now there’s a lawsuit

by Ryan Klingler | Jul 23, 2025 | Media

Kennedy Rescinds Endorsements for Some Flu Vaccines

Kennedy Rescinds Endorsements for Some Flu Vaccines

by Ryan Klingler | Jul 5, 2025 | Media

A pharmacy benefit manager stopped covering a GLP-1 for obesity. Now there’s a lawsuit

Measles cases surge to record high since disease was declared eliminated in the US

by Ryan Klingler | Jun 3, 2025 | Media

How Truveta benchmarks AI model quality for clinical concept extraction

How Truveta benchmarks AI model quality for clinical concept extraction

by Sujatha Sagiraju | May 22, 2025 | News

As machine learning models increasingly assist in interpreting patient records, understanding how to properly evaluate these models becomes crucial for ensuring reliable clinical research outcomes. Jay Nanduri, Truveta CTO, provided an overview of Truveta language...
Wegovy use among US teens up 50% as obesity crisis worsens

Wegovy use among US teens up 50% as obesity crisis worsens

by Ryan Klingler | May 21, 2025 | Media

« Older Entries
Next Entries »

Share this


Recent posts

  • CDC publishes national COVID-19 analysis using Truveta Data
  • The FDA just changed the rules. Here’s what we owe patients.
  • With the FDA ending the two-trial default, the era of intelligent evidence has begun

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Research

Resources

Blog

News

Careers

Privacy notice

Contact us

© Truveta 2026

Our website uses cookies to ensure you have the best experience.